Welcome to our dedicated page for Cheelcare news (Ticker: CHCRF), a resource for investors and traders seeking the latest updates and insights on Cheelcare stock.
Cheelcare Inc. reports news on the commercialization of its advanced mobility products, including the Companion power assist device line and the Curio robotic complex-rehab power wheelchair. Recurring updates cover bookings, unit sales, request-for-quotation activity, dealer engagement, production activity, and reimbursement-supported access for Companion through U.S. Medicare and Medicaid eligibility.
Company news also covers financial results, manufacturing and quality-system updates, investor-conference participation, and capital actions such as unsecured note financing. These developments describe Cheelcare’s role as a Canadian mobility-device manufacturer serving disability, rehabilitation, clinician, therapist, dealer, and funding-agency channels.
Cheelcare (OTC:CHCRF) reported preliminary record April 2026 bookings for its Companion power-assist line, marking a second straight monthly record. April bookings rose 147% year-over-year and 38.5% sequentially, supported by rising RFQs after U.S. Medicare and Medicaid reimbursement eligibility gained in January 2026.
Cheelcare (OTC: CHCRF) will present at the 2026 Bloom Burton & Co. Healthcare Investor Conference in Toronto on April 21-22, 2026. The company presentation is scheduled for Wednesday, April 22, 2026 at 3:30 PM ET.
CEO Eugene Cherny and VP of Growth Allan Boyd will deliver the presentation and hold one-on-one investor meetings during the conference.
Cheelcare (OTC: CHCRF) delivered its first Curio robotic complex‑rehab power wheelchairs to paying customers on April 9, 2026, marking a move into commercial production and initial revenue generation for its flagship platform.
The company also reported record Companion unit sales in March, growing Medicare and Medicaid reimbursement uptake, an expanding RFQ pipeline, and a new ~16,000 sq. ft. manufacturing facility and assembly line to support scalable production.
Cheelcare (OTC: CHCRF) reported Q3 fiscal results for the quarter ended January 31, 2026, with revenue of $549,857 (16% year-over-year) and net loss of $509,824. Gross margin improved to 44.3%. Key operational wins include U.S. HCPCS reimbursement for Companion, PDAC verification, Health Canada "Compliant" rating, 2,000 cumulative Companion units sold and distribution through over 500 dealer locations. Cash was $83,642 with working capital of $355,047; the company completed a $1.0 million unsecured promissory note financing on February 18, 2026 to support working capital and manufacturing scale-up.
Cheelcare (CHCRF) closed a $1.0 million unsecured note financing on February 18, 2026 by issuing 12% promissory notes. Pathfinder purchased $750,000 and NameSilo purchased $250,000. Notes mature August 11, 2027, are redeemable after one year, and pay semi-annual interest.
The company issued 132,450 bonus shares to lenders equal to 20% of principal at $1.51 per share; proceeds will fund working capital, inventory, manufacturing, and general corporate purposes.
Cheelcare (TSXV: CHER) entered term sheets for a non-brokered unsecured note financing of up to $1,000,000, expected to include $750,000 from Pathfinder Asset Management Ltd. and $250,000 from NameSilo Technologies.
The Notes carry an 18-month term at 12% annual interest, with interest payable semi-annually and principal due at maturity. The company may redeem after one year without penalty. Cheelcare will issue an aggregate 132,450 Bonus Shares (20% of principal over $1.51/share) subject to a four-month hold. Closing remains subject to customary corporate and Exchange approvals.